^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    1d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360
    Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    1d
    Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Virginia Commonwealth University | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date • Checkpoint inhibition • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • HR negative • HER-2 negative + HR negative
    |
    Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • decitabine
    1d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    2d
    Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer (clinicaltrials.gov)
    P=N/A, N=28, Not yet recruiting, Tang-Du Hospital
    New trial
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Qibeian (iparomlimab/tuvonralimab)
    2d
    A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov)
    P1, N=330, Recruiting, Pfizer | Trial completion date: Sep 2028 --> Jan 2029 | Trial primary completion date: Sep 2027 --> Jan 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • Zumrad (sasanlimab)
    4d
    Albumin-bound alkylated resiquimod for enhanced cancer immunotherapy. (PubMed, J Control Release)
    Nanoparticle albumin-bound technology is a highly successful drug delivery platform, exemplified by the development of nab-paclitaxel...When combined with anti-programmed death-1 antibody (αPD-1), CR@BSA significantly suppresses tumor metastasis and induces complete tumor regression in 37.5% of treated mice bearing orthotopic 4 T1 breast tumors. This study provides a simple but effective strategy for the development of albumin-bound nanomedicine to improve cancer immunotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    albumin-bound paclitaxel
    5d
    Comprehensive review of current management and precision medicine in pancreatic cancer. (PubMed, J Chin Med Assoc)
    Systemic therapies, including FOLFIRINOX, gemcitabine plus nab-paclitaxel, and NALIRIFOX, remain the cornerstone of therapies for metastatic disease, with precision medicine offering targeted options such as PARP inhibitors for BRCA-mutated tumors. Modern radiotherapy techniques including stereotactic body radiation therapy and particle therapy enhance local control and reduce toxicity. The integration of next-generation sequencing and multidisciplinary management is essential for improving pancreatic cancer outcomes.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • irinotecan • leucovorin calcium
    5d
    High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=29, Recruiting, Emory University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel
    5d
    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer (clinicaltrials.gov)
    P1, N=21, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel
    6d
    Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, The First Affiliated Hospital of Henan University of Science and Technology
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • Qibeian (iparomlimab/tuvonralimab)
    6d
    A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting
    Enrollment open
    |
    MTAP (Methylthioadenosine Phosphorylase)
    |
    MTAP deletion
    |
    gemcitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • navlimetostat (BMS-986504)
    6d
    TORCHLIGHT: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (clinicaltrials.gov)
    P3, N=531, Completed, Shanghai Junshi Bioscience Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel